The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic ...

Witty’s departure was unexpected, but follows a downturn in the healthcare company’s financial outlook. He will be replaced ...